The mastocytosis drug market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period can be attributed to an aging population, a rising prevalence of blood cancers, increased utilization of biologic and immunotherapies, growing healthcare spending, and a higher incidence of mastocytosis.
The mastocytosis drug market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The projected growth during the forecast period can be attributed to a growing emphasis on rare disease treatments, the emergence of personalized medicine, an increasing incidence of allergies and immune system disorders, greater use of supportive therapies, and an expanding pipeline of drugs in development. Key trends anticipated during this period include progress in medical research, the development of targeted treatment options, advancements in genetic research, the adoption of combination therapy approaches, and innovations in drug delivery technologies.
The rising investment in rare diseases is expected to drive the growth of the mastocytosis drug market in the coming years. Rare diseases are medical conditions that impact a small portion of the population - typically fewer than 200,000 individuals in the United States or fewer than 1 in 2,000 people in Europe. Increased investment in this area is largely fueled by growing regulatory incentives such as orphan drug designations, extended market exclusivity, and tax credits, which help lower development risks and improve profitability for pharmaceutical companies. Mastocytosis drugs provide targeted treatment that not only helps manage mastocytosis symptoms but also contributes to the advancement of therapies for other rare diseases sharing similar immune or cellular pathways. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that in the first quarter of 2024, companies focused on rare disease drug development raised $7.1 billion through public equity and debt financings - a 307% increase compared to the $1.8 billion raised during the same period in 2023. As a result, rising investment in rare diseases is fueling the expansion of the mastocytosis drug market.
Leading companies in the mastocytosis drug market are concentrating on developing innovative treatments such as tyrosine kinase inhibitors to enhance therapeutic effectiveness and offer targeted solutions for patients with advanced mast cell disorders. Tyrosine kinase inhibitors are medications that block enzymes involved in abnormal cell growth. In the context of mastocytosis, these drugs work by inhibiting the excessive growth of mast cells, thereby reducing symptoms like rashes and inflammation. For example, in May 2023, Blueprint Medicines Corporation, a biotechnology company based in the U.S., received approval from the U.S. Food and Drug Administration for Ayvakit (avapritinib) to treat adults with indolent systemic mastocytosis (ISM). This approval represents a significant step forward in managing ISM, a rare and chronic condition marked by the overproduction of mast cells. Ayvakit is a selective inhibitor targeting the KIT D816V mutation, which is commonly found in ISM patients, providing a focused treatment option for symptom control and disease management.
In May 2024, Incyte Corporation, a biopharmaceutical company based in the United States, acquired Escient Pharmaceuticals for approximately $750 million. This acquisition is intended to bolster Incyte’s Inflammation and Autoimmunity (IAI) pipeline by incorporating Escient Pharmaceuticals’ first-in-class oral MRGPR antagonists, thereby enhancing its ability to develop novel therapies for serious immune and neuro-immune conditions. Escient Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing EP262, a first-in-class oral MRGPRX2 antagonist aimed at treating mast cell-mediated diseases.
Major players in the mastocytosis drug market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK plc, Teva Pharmaceutical Industries Limited, Alcon Inc., Bausch Health Companies Inc., Genentech Inc., Lupin Limited, Blueprint Medicines Corporation, Don Valley Pharma (Pvt.) Ltd., Vivan Life Sciences Private Limited, AB Science S.A., Medoz Pharmaceutical Private Limited, Zumax Biocare Private Limited, Hi-Cure Biotech Private Limited, Zenomed Healthcare Private Limited, Biosynth AG.
North America was the largest region in the mastocytosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mastocytosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the mastocytosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Mastocytosis drugs are medications used to treat mastocytosis, a rare disorder marked by the abnormal buildup of mast cells in the skin, bone marrow, and internal organs. These medications are designed to manage symptoms, suppress mast cell activity, or address more aggressive forms of the condition.
The primary types of mastocytosis drugs include antihistamines, corticosteroids, and mast cell stabilizers. Antihistamines serve as first-line treatments by alleviating symptoms through the prevention of histamine from binding to its receptors during allergic responses. These drugs are used to manage conditions such as systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome. They can be administered orally, intravenously, or subcutaneously. Distribution occurs through hospital pharmacies, online pharmacies, retail stores, and other channels. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.
The mastocytosis drug market research report is one of a series of new reports that provides mastocytosis drug market statistics, including the mastocytosis drug industry global market size, regional shares, competitors with the mastocytosis drug market share, detailed mastocytosis drug market segments, market trends, and opportunities, and any further data you may need to thrive in the mastocytosis drug industry. This mastocytosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The mastocytosis drug market also includes sales of antihistamines, leukotriene receptor antagonists, corticosteroids, tyrosine kinase inhibitors (TKIs), and epinephrine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The mastocytosis drug market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The projected growth during the forecast period can be attributed to a growing emphasis on rare disease treatments, the emergence of personalized medicine, an increasing incidence of allergies and immune system disorders, greater use of supportive therapies, and an expanding pipeline of drugs in development. Key trends anticipated during this period include progress in medical research, the development of targeted treatment options, advancements in genetic research, the adoption of combination therapy approaches, and innovations in drug delivery technologies.
The rising investment in rare diseases is expected to drive the growth of the mastocytosis drug market in the coming years. Rare diseases are medical conditions that impact a small portion of the population - typically fewer than 200,000 individuals in the United States or fewer than 1 in 2,000 people in Europe. Increased investment in this area is largely fueled by growing regulatory incentives such as orphan drug designations, extended market exclusivity, and tax credits, which help lower development risks and improve profitability for pharmaceutical companies. Mastocytosis drugs provide targeted treatment that not only helps manage mastocytosis symptoms but also contributes to the advancement of therapies for other rare diseases sharing similar immune or cellular pathways. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that in the first quarter of 2024, companies focused on rare disease drug development raised $7.1 billion through public equity and debt financings - a 307% increase compared to the $1.8 billion raised during the same period in 2023. As a result, rising investment in rare diseases is fueling the expansion of the mastocytosis drug market.
Leading companies in the mastocytosis drug market are concentrating on developing innovative treatments such as tyrosine kinase inhibitors to enhance therapeutic effectiveness and offer targeted solutions for patients with advanced mast cell disorders. Tyrosine kinase inhibitors are medications that block enzymes involved in abnormal cell growth. In the context of mastocytosis, these drugs work by inhibiting the excessive growth of mast cells, thereby reducing symptoms like rashes and inflammation. For example, in May 2023, Blueprint Medicines Corporation, a biotechnology company based in the U.S., received approval from the U.S. Food and Drug Administration for Ayvakit (avapritinib) to treat adults with indolent systemic mastocytosis (ISM). This approval represents a significant step forward in managing ISM, a rare and chronic condition marked by the overproduction of mast cells. Ayvakit is a selective inhibitor targeting the KIT D816V mutation, which is commonly found in ISM patients, providing a focused treatment option for symptom control and disease management.
In May 2024, Incyte Corporation, a biopharmaceutical company based in the United States, acquired Escient Pharmaceuticals for approximately $750 million. This acquisition is intended to bolster Incyte’s Inflammation and Autoimmunity (IAI) pipeline by incorporating Escient Pharmaceuticals’ first-in-class oral MRGPR antagonists, thereby enhancing its ability to develop novel therapies for serious immune and neuro-immune conditions. Escient Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing EP262, a first-in-class oral MRGPRX2 antagonist aimed at treating mast cell-mediated diseases.
Major players in the mastocytosis drug market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK plc, Teva Pharmaceutical Industries Limited, Alcon Inc., Bausch Health Companies Inc., Genentech Inc., Lupin Limited, Blueprint Medicines Corporation, Don Valley Pharma (Pvt.) Ltd., Vivan Life Sciences Private Limited, AB Science S.A., Medoz Pharmaceutical Private Limited, Zumax Biocare Private Limited, Hi-Cure Biotech Private Limited, Zenomed Healthcare Private Limited, Biosynth AG.
North America was the largest region in the mastocytosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mastocytosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the mastocytosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Mastocytosis drugs are medications used to treat mastocytosis, a rare disorder marked by the abnormal buildup of mast cells in the skin, bone marrow, and internal organs. These medications are designed to manage symptoms, suppress mast cell activity, or address more aggressive forms of the condition.
The primary types of mastocytosis drugs include antihistamines, corticosteroids, and mast cell stabilizers. Antihistamines serve as first-line treatments by alleviating symptoms through the prevention of histamine from binding to its receptors during allergic responses. These drugs are used to manage conditions such as systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome. They can be administered orally, intravenously, or subcutaneously. Distribution occurs through hospital pharmacies, online pharmacies, retail stores, and other channels. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.
The mastocytosis drug market research report is one of a series of new reports that provides mastocytosis drug market statistics, including the mastocytosis drug industry global market size, regional shares, competitors with the mastocytosis drug market share, detailed mastocytosis drug market segments, market trends, and opportunities, and any further data you may need to thrive in the mastocytosis drug industry. This mastocytosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The mastocytosis drug market also includes sales of antihistamines, leukotriene receptor antagonists, corticosteroids, tyrosine kinase inhibitors (TKIs), and epinephrine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Mastocytosis Drug Market Characteristics3. Mastocytosis Drug Market Trends And Strategies4. Mastocytosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Mastocytosis Drug Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Mastocytosis Drug Market34. Recent Developments In The Mastocytosis Drug Market
5. Global Mastocytosis Drug Growth Analysis And Strategic Analysis Framework
6. Mastocytosis Drug Market Segmentation
7. Mastocytosis Drug Market Regional And Country Analysis
8. Asia-Pacific Mastocytosis Drug Market
9. China Mastocytosis Drug Market
10. India Mastocytosis Drug Market
11. Japan Mastocytosis Drug Market
12. Australia Mastocytosis Drug Market
13. Indonesia Mastocytosis Drug Market
14. South Korea Mastocytosis Drug Market
15. Western Europe Mastocytosis Drug Market
16. UK Mastocytosis Drug Market
17. Germany Mastocytosis Drug Market
18. France Mastocytosis Drug Market
19. Italy Mastocytosis Drug Market
20. Spain Mastocytosis Drug Market
21. Eastern Europe Mastocytosis Drug Market
22. Russia Mastocytosis Drug Market
23. North America Mastocytosis Drug Market
24. USA Mastocytosis Drug Market
25. Canada Mastocytosis Drug Market
26. South America Mastocytosis Drug Market
27. Brazil Mastocytosis Drug Market
28. Middle East Mastocytosis Drug Market
29. Africa Mastocytosis Drug Market
30. Mastocytosis Drug Market Competitive Landscape And Company Profiles
31. Mastocytosis Drug Market Other Major And Innovative Companies
35. Mastocytosis Drug Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Mastocytosis Drug Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on mastocytosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for mastocytosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mastocytosis drug market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Antihistamines; Corticosteroids; Mast Cell Stabilizers2) By Disease Type: Systemic Mastocytosis; Cutaneous Mastocytosis; Mast Cell Activation Syndrome
3) By Route Of Administration: Oral; Intravenous; Subcutaneous
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retailers; Other Distribution Channels
5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Antihistamines: H1-Receptor Antagonists; H2-Receptor Antagonists2) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Intravenous Corticosteroids
3) By Mast Cell Stabilizers: Cromolyn sodium; Ketotifen; Nedocromil
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; Bayer AG; Sanofi S.A.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- Bayer AG
- Sanofi S.A.
- Novartis AG
- GSK plc
- Teva Pharmaceutical Industries Limited
- Alcon Inc.
- Bausch Health Companies Inc.
- Genentech Inc.
- Lupin Limited
- Blueprint Medicines Corporation
- Don Valley Pharma (Pvt.) Ltd.
- Vivan Life Sciences Private Limited
- AB Science S.A.
- Medoz Pharmaceutical Private Limited
- Zumax Biocare Private Limited
- Hi-Cure Biotech Private Limited
- Zenomed Healthcare Private Limited
- Biosynth AG